Mortality within 30 days of receiving systemic anti-cancer therapy at a regional oncology unit: what have we learned?
OBJECTIVE
Benefits to patients from systemic anti-cancer therapies (SACT) occur at a cost of significant toxicities that can be life threatening. Published data of SACT mortality outside clinical trials is limited with no published Australia data. We aim to establish local outcomes at a regional Victorian oncology center to allow comparison with limited international data.


METHODS
An audit was undertaken at Ballarat Health Services to analyze all deaths occurring within 30 and 60 days of receiving SACT (cytotoxic chemotherapy and targeted therapy) for epithelial malignancies and hematological malignancies (excluding acute leukemia), over a 12-month period. Hormonal therapy was excluded.


RESULTS
Between 1 January and 31 December 2008, 378 patients received SACT. In total 13 deaths (3.4%) occurred within 30 days following SACT. Three deaths (23%) were definitely treatment-related - neutropenic sepsis, pneumocystis pneumonia and bowel perforation, respectively. Eight deaths (62%) were definitely unrelated to treatment. Most deaths were due to disease progression (six patients) For two patients (15%), the cause of death was unknown. Most patients were treated with palliative intent. Most patients were receiving first-line treatment (seven patients, 50%). A further five deaths (1.3%) occurred 31-60 days after SACT, four of which were due to disease progression.


CONCLUSIONS
Our local outcome data are comparable to limited current international data. This type of audit reviews local outcomes and identifies factors contributing to mortality in order to improve standards of care. We encourage similar audits to establish national benchmarks of 30-day mortality rate.
Ballarat Base Hospital, Ballarat Health Services, Ballarat, Victoria 3350, Australia.
Jaclyn
J
Yoong
Jo-An
JA
Seah
Katherine
K
Hamilton
Lee Na
LN
Teo
Geoffrey
G
Chong
D000368:Aged; D003133:Commission on Professional and Hospital Activities; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D012189:Retrospective Studies; D016019:Survival Analysis; D014739:Victoria / Q000453:epidemiology